1. Home
  2. SUMA vs VYGR Comparison

SUMA vs VYGR Comparison

Compare SUMA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SUMA

SUMA Acquisition Corporation Class A Ordinary Shares

N/A

Current Price

$9.96

Market Cap

232.1M

Sector

N/A

ML Signal

N/A

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

N/A

Current Price

$2.45

Market Cap

193.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SUMA
VYGR
Founded
2025
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.1M
193.5M
IPO Year
2026
2015

Fundamental Metrics

Financial Performance
Metric
SUMA
VYGR
Price
$9.96
$2.45
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $14.89
AVG Volume (30 Days)
11.1K
★ 584.2K
Earning Date
N/A
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $10,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$129.75
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.87
$2.33
52 Week High
$10.11
$5.55

Technical Indicators

Market Signals
Indicator
SUMA
VYGR
Relative Strength Index (RSI) 54.24 27.89
Support Level $9.89 N/A
Resistance Level $10.11 $3.30
Average True Range (ATR) 0.02 0.13
MACD -0.00 -0.03
Stochastic Oscillator 28.57 12.57

Price Performance

Historical Comparison
SUMA
VYGR

About SUMA SUMA Acquisition Corporation Class A Ordinary Shares

Suma Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: